Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rallybio Corporation - Common Stock (NQ:RLYB)

4.800 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Rallybio Corporation - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Rallybio Announces Acceptance of Abstract for RLYB212 at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH)
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Reports Fourth Quarter and Full Year 2022 Financial Results
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Announces Proof-of-Concept Achieved for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio to Present at Upcoming Investor Conferences in March
From Rallybio Corporation
Via Business Wire
News headline image
EyePoint and Rallybio Announce Research Collaboration to Evaluate Rallybio’s Inhibitor of Complement Component 5 (C5) and EyePoint’s Proprietary Durasert® Technology for Sustained Intraocular Delivery in Geographic Atrophy
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Announces Appointment of Jonathan I. Lieber as Chief Financial Officer
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2023
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Announces Publication of Data Highlighting the Ability of HPA-1a-Specific Antibodies to Prevent Alloimmunization in an Authentic Mouse Model of FNAIT
From Rallybio Corporation
Via Business Wire
News headline image
AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio to Present at the JMP Securities Hematology and Oncology Summit
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio to Present at Upcoming Investor Conferences in November
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Announces Pricing of $50 Million Public Offering
From Rallybio
Via Business Wire
News headline image
Rallybio Announces Proposed Public Offering
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Reports Third Quarter 2022 Financial Results
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Announces Positive Phase 1 Single Ascending Dose Results for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Announces Positive Preliminary Results for RLYB212, an anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio to Present at the 2022 Wells Fargo Healthcare Conference
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Reports Second Quarter 2022 Financial Results
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Appoints Wendy K. Chung, M.D., Ph.D., to Its Board of Directors
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Announces Retirement of Jeffrey Fryer, CPA, Chief Financial Officer
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio to Present at Upcoming Investor Conferences in June
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Reports First Quarter 2022 Financial Results
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Announces In-Licensing of Potential First-In-Class Preclinical Antibody Candidate from Sanofi
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Appoints Christine A. Nash and Hui Liu, Ph.D., to Its Board of Directors
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Reports Fourth Quarter and Full Year 2021 Financial Results
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio to Present at the Cowen 42nd Annual Health Care Conference
From Rallybio Corporation
Via Business Wire
News headline image
Ami Bavishi Joins Rallybio to Lead Investor Relations and Corporate Communications
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Highlights Portfolio Advances and Outlines Expected Upcoming Milestones for 2022
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Reports Positive Data in Its Clinical Program for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
From Rallybio Corporation
Via Business Wire
News headline image
Rallybio Corporation to Present at the 4th Annual Evercore ISI HealthCONx Conference
From Rallybio Corporation
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.